Regeneron Reports Mixed Q4/FY25 Results, Strong Dupixent/EYLEA HD Growth, Key Regulatory Approvals
Summary
Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing strong growth in Dupixent and EYLEA HD sales, alongside significant regulatory approvals and pipeline advancements, despite a decline in overall EYLEA franchise sales.
Key Events
-
Q4/FY25 Financial Performance
Reported Q4 revenues increased 3% to $3.9 billion, with full year revenues up 1% to $14.3 billion. Q4 GAAP EPS decreased 2% to $7.86, while full year GAAP EPS increased 8% to $41.48.
-
Dupixent & EYLEA HD Drive Growth
Dupixent global net sales surged 34% to $4.9 billion in Q4, and EYLEA HD U.S. net sales increased 66% to $506 million, significantly offsetting a 28% decline in total EYLEA franchise U.S. sales.
-
Multiple Regulatory Approvals
Secured FDA approval for EYLEA HD in macular edema following retinal vein occlusion (RVO) and for monthly dosing flexibility, EC approval for Dupixent in chronic spontaneous urticaria (CSU), and FDA/EC approvals for Libtayo in high-risk adjuvant cutaneous squamous cell carcinoma (CSCC).
-
Pipeline Advancements & Investments
Submitted Biologics License Applications (BLAs) for DB-OTO (gene therapy for hearing loss) and garetosmab (fibrodysplasia ossificans progressiva), and announced a $2 billion investment in a new manufacturing facility.
Analysis
Regeneron's latest earnings report highlights a strategic transition within its key product portfolio, with robust growth from Dupixent and EYLEA HD largely compensating for the decline in the legacy EYLEA product. The numerous regulatory approvals across its therapeutic areas, coupled with significant pipeline advancements and a substantial investment in manufacturing, underscore the company's commitment to long-term growth and innovation. Investors should monitor the continued market penetration of EYLEA HD and Dupixent, as well as the progress of newly submitted regulatory applications and the impact of the new manufacturing facility on future capacity and efficiency.
At the time of this filing, REGN was trading at $740.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $78.8B. The 52-week trading range was $476.49 to $821.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.